Advanced Medical Optics (AMO, Santa Ana, CA) redefined its position in the ophthalmic community when it reached a definitive agreement April 21 to acquire Pfizer’s surgical ophthalmology business for $450 million in cash. The deal will boost AMO’s revenue base by 25% and allow the company bragging rights to the Healon line of viscoelastic products, the CeeOn and Tecnis IOLs, and the Baerveldt glaucoma shunt.“You don’t see many of these deals come across in a lifetime-in any industry,” said AMO President and Chief Executive Officer James V. Mazzo
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.